This led to the activation of nuclear factor erythroid 2-related factor 2 (Nrf2) signaling, and that these mechanistic modifications resulted in improved sensitivity of pancreatic cancer cells to gemcitabine [113]. This evidence concerns the gene NFE2L2 and pancreatic neoplasm.